4D Mol­e­c­u­lar paus­es en­roll­ment in Fab­ry tri­als af­ter kid­ney prob­lems in three pa­tients

4D Mol­e­c­u­lar Ther­a­peu­tics said it has stopped en­rolling pa­tients in its two clin­i­cal tri­als of a gene ther­a­py be­ing in­ves­ti­gat­ed for Fab­ry dis­ease.

The biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER